Literature DB >> 2659088

Therapeutic effect of chloroquine(CQ)-containing immunoliposomes in rats infected with Plasmodium berghei parasitized mouse red blood cells: comparison with combinations of antibodies and CQ or liposomal CQ.

P A Peeters1, B G Brunink, W M Eling, D J Crommelin.   

Abstract

The potential therapeutic application of chloroquine-containing immunoliposomes (Fab'-lipCQ) in a Plasmodium berghei malaria model was studied. Extending a previously described in vivo model (Peeters et al. (1988) Biochim. Biophys. Acta 943, 137-147) it was demonstrated that injection of antimouse red blood cell (anti-mRBC) Fab'-lipCQ was significantly more effective than liposome-encapsulated chloroquine (lipCQ) or free chloroquine in delaying or preventing a patent infection after intravenous injection of parasitized mouse red blood cells (p-mRBC) in rats. The results could be improved by injecting synchronized infected cells instead of non-synchronous p-mRBC in order to minimize the presence of free parasites which could easily infect rat RBC. It was further demonstrated that sequential injection of anti-mRBC IgG and lipCQ or chloroquine resulted in complete inactivation of the injected parasitized cells while Fab'-lipCQ administration resulted in a maximum score of 50% at an equal chloroquine, protein and phospholipid dose. In this report the potential of the concept of drug targeting for the effective treatment of a disease, which manifests in blood cells, was demonstrated.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2659088     DOI: 10.1016/0005-2736(89)90037-0

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  Chloroquine blood levels after administration of the liposome-encapsulated drug in relation to therapy of murine malaria.

Authors:  P A Peeters; K de Leest; W M Eling; D J Crommelin
Journal:  Pharm Res       Date:  1989-09       Impact factor: 4.200

2.  Inhibition of the Growth of Plasmodium falciparum in Culture by Stearylamine-Phosphatidylcholine Liposomes.

Authors:  Gulam Mustafa Hasan; Neha Garg; Enna Dogra; Ranu Surolia; Prahlad Chandra Ghosh
Journal:  J Parasitol Res       Date:  2011-06-14

3.  Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies.

Authors:  D Goren; A T Horowitz; S Zalipsky; M C Woodle; Y Yarden; A Gabizon
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

Review 4.  Nanomedicine Reformulation of Chloroquine and Hydroxychloroquine.

Authors:  David M Stevens; Rachael M Crist; Stephan T Stern
Journal:  Molecules       Date:  2020-12-31       Impact factor: 4.411

5.  A systematic screen of FDA-approved drugs for inhibitors of biological threat agents.

Authors:  Peter B Madrid; Sidharth Chopra; Ian D Manger; Lynne Gilfillan; Tiffany R Keepers; Amy C Shurtleff; Carol E Green; Lalitha V Iyer; Holli Hutcheson Dilks; Robert A Davey; Andrey A Kolokoltsov; Ricardo Carrion; Jean L Patterson; Sina Bavari; Rekha G Panchal; Travis K Warren; Jay B Wells; Walter H Moos; Raelyn L Burke; Mary J Tanga
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

6.  Improvement of therapeutic effect by using Fab' fragment in the treatment of carcinoembryonic antigen-positive human solid tumors with adriamycin-entrapped immunoliposomes.

Authors:  I Uyama; K Kumai; T Yasuda; T Tagawa; K Ishibiki; M Kitajima; T Tadakuma
Journal:  Jpn J Cancer Res       Date:  1994-04

Review 7.  Liposomes for malaria management: the evolution from 1980 to 2020.

Authors:  Patrick B Memvanga; Christian I Nkanga
Journal:  Malar J       Date:  2021-07-27       Impact factor: 2.979

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.